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Abstract: The pharmaceutical sector is a flagship of the economy in most developed countries and
is one of the most research-intensive sectors of modern economies. The aim of this paper was
to determine the mutual relationships between the research and development (R&D) resources,
various indicators of scientific performance and the competitiveness of the sector. We carried out a
cointegration analysis of a time series of R+D resources, the number of academic papers published,
as well as patents and the competitiveness of this sector in various developed states. The econometric
analysis of time series is built on panel cointegration models. Based on the combination of different
comprehensive and coherent international databases and applying the latest methods of modern
time series analysis, the paper proves that, in most developed countries, a direct, significant, causal,
lagged relationship between the monetary resources allocated to R&D and the number of academic
papers, as well as the number of patents can be observed. In most cases, a causal relationship can
be demonstrated between the number of academic papers and patents, but vice versa, this fact is
not provable. This study highlights the complexity of innovation systems in the pharmaceutical
sector. The results prove only a weak connection between the number of patents and the number of
publications. When evaluating the efficiency of the utilisation of resources allocated to pharmaceutical
R+D, the effect of the time lag should be considered.
Keywords: competitiveness; economic policy; international statistics; time series analysis;
pharmaceutical sector
1. Introduction
The pharmaceutical industry is an elementary precondition in the realisation of sustainable
development goals of the United Nations, [1,2]. The complex relation between UN Sustainable
development goals [3] and innovative development of the pharmaceutical sector can be summarised
as follows.
Development of new and cheaper drugs [4] is a necessary precondition for maintaining the health,
motivation and capacities of the population, contributing to the reduction of poverty, which is a basic
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development goal. The production of nutraceuticals and functional food [5] is important to achieve
zero hunger as a development goal. Innovative products [6] contribute to gender equality. New
technologies [7,8] are vital for water and energy conservation. Efforts to enhance the affordability
of pharmaceuticals [9] contribute to the reduction of inequalities. The increasing significance of the
“green chemistry” approach [10–12] in the pharmaceutical industry is a direct contribution to the
decreasing carbon footprint [13], responsible production and consumption, and mitigation of climate
change. The introduction of biodegradable materials [14] and other environmentally sustainable
packages [15,16] help to preserve lifeforms that exist both below the water and on land. As a summary,
it can be stated that the development of the pharmaceutical industry is a key factor to achieve the
sustainable development goals of the UN [17].
The pharmaceutical industry can be characterised as a knowledge-intensive one. That is why it
lends itself as an example for the analysis of the interrelations between financial resources allocated
for research and development, intellectual outputs (patents and publications) and competitiveness.
The goal of the current paper is an econometric analysis of these interrelations. There is an abundance
of literature on the analysis of some aspects of the interrelations of the above factors, but to the best of
our knowledge, the current study is the first attempt (1) to analyse all of these aspects simultaneously,
(2) based on a relatively large number of countries, and a long range of time series, and (3) which
applies the latest methods of econometric research.
2. Literature Review
Innovation is a key determinant of market success [4–8] and an important tool for increasing
the competitiveness of companies as well as regions [9,10]. In addition, it has also been claimed
that the emphasis on social components in the general mainstream of enterprise innovation activity
is one of the strongest reasons for its successful functioning and development [11,12]. There is a
considerable debate on measuring the efficiency of monetary resource allocation on research and
development (RD) [13–15]. Table 1 offers an overview of the most important articles on this topic,
showing the historic development of the analysis of this problem. During the last few decades, there
has been an unprecedented investment in pharmaceutical research and development [16–18], partly
as a consequence of the aging of the population [19]. Hence, understanding the economic effects of
research is especially important for the pharmaceutical sector [20]. The application of traditional R&D
models to the modern pharmaceutical industry is highly controversial [21], and there is an intense
search for more efficient models and methods of R&D in the industry. The results of Achilladelis
and Antonakis [22] have shown a statistically significant positive relationship between originality
and commercial success in the pharmaceutical industry. Pharmaceutical product development is a
very high-cost activity [23]. The seminal paper by [24] has proven that the pre-tax average cost of
new drug development from out-of-pocket costs to the point of marketing approval was more than
USD 230 million in 1987. According to the latest estimations by DiMasi et al. [24], the pre-tax direct
(“out-of-pocket”) cost for approval of a new drug is USD 1.395 billion, with the total R&D costs in
the pre-and post-approval period being USD 2.87 billion. According to official data from the World
Bank, the USD inflation was 214% between 1987 and 2015. That is why it can be stated that new drug
development costs have increased by nearly 500% in real terms in the last three decades. At first sight,
the efficiency of corporate innovation can be directly measured by the effects on stock-prices; however,
this is somewhat indirect evidence [25,26].
The results of Chen and Chang [27] highlight a direct relationship between patent counts and a
firm’s market value in the pharmaceutical sector. Similar results have been obtained by Chang et al. [28],
as well as Korsakiene˙ et al. [23] and Kliestik et al. [29].
In the opinion of numerous specialists, there is an inherent conflict between profit-oriented
and academic (publication-oriented) research [30,31]. This is manifested in the suppression or
delay of the publication of results [32–36]. At the same time, Geuna and Nesta [37] highlight that
publication and patent go hand in hand in the academic world. According to Agrawal and Henderson,
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patenting may play a relatively small role in transferring academic knowledge. In an early publication,
analysing the patenting and publication behaviour of scientists working at large American companies,
Halperin and Chakrabarti [38] proved a positive correlation between publication and patenting activity.
They highlight that capital-intensive sectors (e.g., pharmaceuticals) can be characterised by a high
level of publications, patents, and elite scientists. According to analysis by Massachusetts Institute of
Technology (MIT), there is a negative correlation between patenting and publishing activities. At the
same time, results prove a positive correlation between the patenting and publication activity of
German professors [39]. A similar result has been reported by Wong and Singh on the basis of statistical
analysis of patents and the scientific papers of world-leading universities. Based on a wide-range
literature survey, Bekelman et al. [40] have proven that biomedical research is heavily influenced by
industry. This is why conflicts of interest arising from close industry–academia relations influence
biomedical research. As a summary, it can be stated that the current literature is highly controversial
on the evaluation of relationships between financial resources, academic publications, patents and
competitiveness. The pharmaceutical sector is an important aspect of modern, developed economies
and is of strategic importance [40–42], making its competitiveness a crucial factor.
Table 1. Some results of the application of econometric models to determine economic effects of R&D.
Source Method Results
Coe and Moghadam [43] Aggregate production function for a 20-yearperiod of the economic development of France.
Government infrastructure, business sector
capital, residential capital and research and
development capital have a significant influence
on aggregate production function.
Coe and Helpman [44]
21 Organisation for Economic Co-operation and
Development (OECD) countries and Israel,
economic data from 1971-1990.
Foreign R&D has a positive effect on domestic
factor productivity, but this depends on the
openness of the economy. High rates of return of
R&D in domestic output and international
spillovers.
Thirtle et al. [45] Ten EU countries and the USA, agriculture,cointegration.
Total Factor Productivity (TFP) calculations,
returns to R&D are seriously biased if spillovers
are ignored.
Funk [46]
Trade patterns and international spillovers of
OECD countries and Kao et al. [47] panel
cointegration model.
There is no significant relationship between
import patterns and R&D spillovers, exporters
receive significant R&D spillover from customers.
Edmond [48]
Pedroni’s test for panel cointegration to
determine the coefficients, estimated in Coe and
Helpman [44] model.
Cointegration coefficients are less robust when
more heterogeneity is allowed; the elasticity
coefficient of productivity on foreign R&D is
unstable.
del Barrio-Castro et al. [49] OECD database. Average years of schooling influence the effect ofinternational R&D.
Gutierrez and Gutierrez [50] Panel data on TPF productivity from 47countries in a 32-year period.
TFP is influenced by domestic and international
R&D, a significant role of geographical location.
Liu [51]
Cointegration analysis on R&D input intensity
and independent innovation ability of Chinese
enterprises on the basis of enterprise-level data
from between 1991 and 2003.
Bi-directional mutual relationship and stable
long-term equilibrium between R&D intensity
and innovation.
Yoo [52] Long- and short-run causality between publicand private R&D expenditure in Korea.
Bi-directional causality between private and
public R&D.
Bottazzi and Peri [53] Employment in R&D and patent applications inOECD countries.
Knowledge spillovers are sufficiently strong to
create long-run endogenous growth.
Coe and Helpman [44] 21 OECD countries and Israel, economic datafrom 1971–2004.
TFP, domestic and foreign R&D capital are
cointegrated; human capital is cointegrated with
Total Factor Productivity (TFP); considerable
differences between countries.
Frantzen [54]
Panel cointegration test on the effect of
domestic and foreign R&D on the productivity
base of 22 manufacturing sectors of 14 OECD
countries between 1972 and 1994.
Log of TFP and logs of domestic and foreign
R&D are cointegrated. Dynamic Vector
Autoregressive (VAR) model suggests that, in the
majority of sectors, causation runs from the R&D
are cointegrated. A dynamic VAR model
suggests that, in the majority of sectors, causation
runs from the R&D variables to TFP, a long-run
causation in nature.
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Table 1. Cont.
Source Method Results
Teixeira and Fortuna [55] Portugal data from 1960 to 2001, cointegration. Significant effect of human capital and R&Defforts on TFP.
Cho et al. [56] Oil prices, energy consumption and R&D in EUcountries, cointegration.
Significant role of R&D on renewable energy
consumption.
Voutsinas and Tsamadias [57] Greek economic data 1987–2007 to determineeffect of public and private R&D on TFP.
A 1% increase in the total R&D capital increases
TFP by 0.038%, whereas a 1% increase in the
public R&D capital raises TFP by 0.075%.
Khan and Salim [58] Australian country level data on R&D and TFPbetween 1953 and 2009.
Cointegration between R&D and productivity
growth, unidirectional causality from R&D to
TFP.
Sussex et al. [59] Medical research costs in UK between 1982 and2012.
A 1% increase in public sector expenditure is
associated with a 0.81% increase in private sector
expenditure.
Meyer and Meyer [60]
Brazil, Russia, India, China and South Africa
(BRICS) data on relationships between
economic growth, employment and established
business ownership
Established business ownership is a significant
predictor of employment
Source: Authors’ own editing, 2019.
Consequently, it can be stated that all over the world there is an intense debate on mutual
relationships among academic productivity (PUBL), intellectual property (PAT), R&D resources (RD)
and competitiveness, measured by the Balassa index of revealed comparative advantages (RCA),
trade specialisation index (TCP) and the Volrath index of competitive advantages (VRCA). The global
pharmaceutical industry is a research-intensive, highly innovative sphere of the global economy,
offering opportunities to study and understand the dynamics of these processes. The results of this
analysis can be applied to the formation of R&D strategies in different countries.
3. Hypothesis Development
As a summary of the literature survey, it can be stated that there are considerable gaps in our
knowledge of the relationships among finance, academic performance, patenting and competitiveness,
as (1) the majority of previous research was based on panel time series, which necessarily contains a
high level of data agglomeration.
This can be explained by a previous lack of time series which satisfied the minimal demands in
terms of length for a reliable, country-level time series analysis (at least 20–23 years). (2) There are
no sector-specific, internationally comparable results for pharmaceutical R&D and competitiveness
analysis. Based on the results of previous research, four hypotheses have been developed.
These state that there is a positive, significant, time-lagged causative relationship between (H1):
financial resources allocated to R&D in the pharmaceutical industry and the academic performance
(measured by number of publications) in pharmacy; (H2): financial resources and the number of
patents; (H3): academic performance and the Balassa index of competitiveness; (H4): the number of
patents and the competitiveness of the sector; (H5): academic performance (number of publications)
and the number of patents; (H6): the number of patents and academic performance; (H7): material
resources allocated to RD and the competitiveness of the sector. The system of the hypotheses of our
paper is summarised in Figure 1.
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4. Methodology
4.1. Databases
The electronic database of the OECD served as the primary database of the research (OECD,
2016) for deriving R&D data and performance in the pharmaceutical industry in the states examined.
The OECD consists of 34 countries, but there was a lack of data for detailed analysis in a considerable
number of countries. This comprehensive website has a section dedicated to socio-economic data on
OECD member states and numerous further important economic entities. The database has been built
based on a wide range of national and international statistical data and contains comparable data in a
transparent form [61,62]. Although most of the available time series embrace the period 1990–2013, in
some cases, the time series are longer. Due to differences in national statistical systems, the time series
are relatively sparse. The OECD database contains economic data on Current International Dollar,
taking into consideration the differences in the purchasing power parity of national currencies [63].
To make the current prices comparable, we have recalculated the data to the 2011 USD value, based on
the World Bank database [64]. Data on academic publications have been collected with the help of the
Web of Science™ (hereinafter: WoS) system of the Institute for Scientific Information (ISI, now part of
Thomson Reuters). There are some arguments for using its most important competitor, Scopus, of
Reed Elsevier [15,65,66]; however, based on the number of papers and citations, largely independent of
the field of science, an extremely high correlation between the “performance” of these two databases
has been proven. The rigorous, systematic analysis of academic publications began only a few decades
ago [67], but the publication and patent data can offer a longer time series.
We have applied the publication data starting from 1990, because (1) the other-economic-time
series are shorter, and (2) as a consequence of the rapid proliferation of published papers, there has
been a structural brake on the trend of statistics publications in the last few decades. The same is
true for general publications. The structure of the data used for the analysis is presented in Table 2.
Data were organised and manipulated on an Excel worksheet. Among the experts dealing with time
series analysis, there is a considerable (but rather informal) debate on the necessary length of time
series to apply for analysis. Granger, one of the “founding fathers” of modern time series analysis,
remarks that the “most important macroeconomics series are rather short”. That is why he would
conduct a “post-sample” evaluation of time series and suggest the application of “cross-validation
techniques”; however, he does not offer any sample size formula. We have applied the rule that time
series must have at least 20 data registered to be selected as a basis for analysis.
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Table 2. Structure of input data (countries with time series available for at least 20 years are indicated
by black cells, however, time series that were too short have been excluded from the analysis indicated
by white cells).
Countries Pharm R&D Pharm Export Pharm Patents Publications
Australia X X X X
Austria X X X
Belgium X X X X
Canada X X X
Chile X
Czech Republic X X X
Denmark X X X
Estonia X X
Finland X X X
France X X X X
Germany X X X X
Greece X X X
Hungary X X X X
Iceland X X X
Ireland X X
Israel X X X X
Italy X X X X
Japan X X X
Korea X X X
Luxemburg X X
Mexico X X X
Netherlands X X X
New Zealand X X
Norway X X X
Poland X X
Portugal X X
Slovak Republic X
Slovenia X X X
Spain X X X
Sweden X X X
Switzerland X X X
Turkey X X
United Kingdom X X X
United States X X X
Source: Authors’ own research, 2019.
4.2. Models Applied
This indicator is generally accepted and widely applied for analysis of the competitiveness of
different sectors around the world (e.g., Freund and Pierola [68]). The original index of revealed
comparative advantage:
RCAi j =
xi j
Σx j
x j
Σx j
,
where j is the exported product category, i is the economic entity (in most cases, a country) under
investigation, Σxi denotes the total export of country i, and Σxj symbolises the total export of product j
in the world. In the last few decades, various alternative measures have been proposed to modify the
original index, although this form has remained the most popular [69]. To avoid any bias, we have
determined the relative position of the pharmaceutical industry in states of investigation on the basis
of the trade specialisation coefficient (TSC).
This coefficient is calculated as follows:
TSC =
(xi j − yi j)
(xi j + yi j)
,
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where xij is the export value of the product j in I country and yij is import of product j in country i.
A higher TSC value indicates a higher level of export competitiveness of a given country, while a lower
TSC value indicates a lower level of competitiveness [70]. This indicator has been applied for analysis
of the Indian pharmaceutical sector by Mahajan et al. [71].
To obtain a clearer picture, we have determined the Vollrath index of relative trade advantage:
this indicator is the difference between revealed competitive advantage in exports and imports [72].
It is well documented that a relatively short time span of data can decrease the power of individual
unit root tests [73]; therefore, in the second part of this paper, the panel cointegration analysis method
is applied to overcome this problem. The cointegration analysis of panel data consists of four steps:
(1) test for a panel unit root; (2) test for cointegration data by employing the heterogeneous panel
cointegration tests; (3) the long-run relationship is estimated for heterogeneous cointegrated panels;
(4) once the panel cointegration is established, we establish a panel error correction model to examine
short-run and long-run causalities between R&D resources, intellectual outputs and different indicators
of competitiveness.
In this research, three types of panel unit root tests have been applied. The first one is the
panel-based unit root test of Levin et al. [74], which allows for individual (in our case: country-specific)
intercepts, and the degree of persistence in individual regression error and trend coefficients to vary
across different entities. According to Ladu and Meleddu [75], this test is relevant for panels of moderate
size, but in some cases, contemporaneous correlations cannot be removed by simple subtraction of
cross-sectional averages. Another problem is that the assumption of the identity of entities with
respect to the presence or absence of a unit root is restrictive. That is why we have cross-checked our
results using the second test developed by Im et al. [76]. This approach is not as restrictive as the
Levin–Lin–Chu test because it allows the heterogeneity of coefficients. The Fisher test is an application
of augmented Dickey–Fuller and Phillips–Perron tests for panel data and “is widely recommended”
according to literature survey of Maddala and Wu [77].
The panel cointegration has been analysed by Pedroni [78] and Kao et al. [47] using Fischer tests,
as well as Fischer [79]. The Pedroni test allows for heterogeneity in the long-run cointegration vectors
and in the dynamics associated with short-run deviation from long-range vectors among panel entities.
This test system is based on asymptotic distributions of seven different statistics: four of them are
based on pooling along the within-dimension (panel cointegration statistics) and three are built on
pooling along the between-dimension (mean panel cointegration statistics). The results of Wagner
and Hlouskova [80] show that the efficiency of the Pedroni test is relatively low in the case of small
samples and short time series; therefore, we have cross-checked our results by Kao and Fischer tests.
The aim of the panel cointegration procedure is the identification of any long-run relationship
between the investigated variables. If this relationship is proven, there is a possibility to determine
long-range relations between different variables [81]. For this purpose, we have applied the
Dumitrescu–Hurlin test of causality [82]. We have considered the model, including lagged dependent
variables correlated with the error term. The Arellano and Bond [83] algorithm has been applied to
determine the relations between different variables.
The short-run responses of variables on changes in the value of another variable has been tested
by the Dumitrescu–Hurlin test of causality of [82], as well as an ordinal least square technique.
The fixed-effect ordinary least squares (FE–OLS) model assumes that each entity (in this case, a country)
is different, and individual heterogeneity can be characterized by an individual intercept. If the error
terms are correlated, the random-effect model (RE–OLS) should be used Hoechle [84]. We have tested
whether the fixed effect is preferred over the random effects based on the Hausman test [85]. The null
hypothesis of this test is that the random effects model is appropriate (difference in coefficients is not
systematic).
One of the basic concepts of our research is the causality between the investigated time series [86].
According to the classic definition of causality, “X is said to Granger-cause Y if Y can be better predicted
using the histories of both X and Y than it can be by using the history of Y alone.” The absence of
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Granger causality has been tested by the following Vector Autoregression (VAR) model: (2) There
are different methods of causality testing (e.g., Lütkepohl and Netšunajev [87]). In this analysis,
we have applied the Toda–Yamamoto procedure [88], which allows us to derive robust conclusions.
The level of integration of time series has been checked by an Augmented Dickey–Fuller test and
Kwiatkowski–Phillips–Schmidt–Shin (KPSS) test algorithm using the Eviews 8.1 program package [89].
The lags have been determined on the basis of the Akaike Information Criterium. The competitive
position of the pharmaceutical industries of various countries has been characterised on the basis of
the revealed comparative advantage index, developed by Balassa [90].
The availability of data has been a limitation to our research from the aspects of the methods
applied. In the case that more data is available for the four variables analysed, the panel cointegration
approach could be applied, but under the current conditions, the simple method used offered more
pieces of practically relevant information.
5. Results and Discussion
Panel unit root tests have been performed both on levels and first differences of the variables and
both with constant and with constant and trend in Table 3.
Table 3. Results of Levin–Lin–Chu (LLC), Imm–Pesharan–Shinn (IPS), Individual Root Augmented
Dickey–Fuller (ADF–Fisher) and Phillips–Person panel cointegration test (PP–Fisher) tests.
Variables LLC IPS ADF-FischerChi-Square
PP-Fischer
Chi-Square
RD
(level)
Individual intercept −5.234 *** [0.000] −1.544* [0.061] 49.333 [0.148] 84.399 *** [0.000]
Individual intercept and trend −2.695 *** [0.003] −1.562 * [0.059] 66.904 *** [0.004] 149.502 *** [0.000]
None 7.160 [1.000] 7.156 [1.000] 6.810 [1.000]
D(RD)
(first
difference)
Individual intercept −18.925 *** [0.000] −19.217 *** [0.000] 342.403 *** [0.000] 361.865 *** [0.000]
Individual intercept and trend −15.693 *** [0.000] −18.439 *** [0.000] 333.197 *** [0.000] 638.538 *** [0.000]
None −18.571 *** [0.000] 374.320 *** [0.000] 448.052 *** [0.000]
PUBL
(level)
Individual intercept −3.061 [1.000] 0.112 [0.544] 54.506 * [0.062] 66.279 * [0.005]
Individual intercept and trend −2,870 *** [0.002] −2.665 *** [0.004] 72.375 *** [0.001] 123.359 *** [0.000]
None −5.658 [1.000] 2.273 [1.000] 2.084 [1.000]
D(PUBL)
(first
difference)
Individual intercept −2.695 *** [0.003] 22.810 *** [0.000] 405.735 *** [0.000] 615.071 *** [0.000]
Individual intercept and trend 7.160 [1.000] −20.744 *** [0.000] 390.392 *** [0.000] 480.876 *** [0.000]
None −18.925 *** [0.000] 505.227 *** [0.000] 615.071 *** [0.000]
PAT
(level)
Individual intercept −14.903 *** [0.000] −11.680 *** [0.000] 209.145 *** [0.000] 260.677 *** [0.000]
Individual intercept and trend −3.065 *** [0.001] −2.240 ** [0.012] 96.586 *** [0.000] 127.755 *** [0.000]
None 3.602 [0.998] 19.257 [0.997] 33.986 [0.736]
D(PAT)
(first
difference)
Individual intercept −10.599 *** [0.000] −17.094 *** [0.000] 297.268 *** [0.000] 407.650 *** [0.000]
Individual intercept and trend −13.129 *** [0.000] −23.971 *** [0.000] 524.793 *** [0.000] 2196.161 *** [0.000]
None −21.375 *** [0.000] 463.554 *** [0.000] 601.177 *** [0.000]
RCA
(level)
Individual intercept −9.789 *** [0.000] −12.650 *** [0.000] 230.343 *** [0.000] 250.925 *** [0.000]
Individual intercept and trend −15.050 *** [0.000] −13.905 *** [0.000] 237.923 *** [0.000] 288.850 *** [0.000]
None −2.232 ** [0.012] 233.120 *** [0.000] 262.656 *** [0.000]
D(RCA)
(first
difference)
Individual intercept −37.299 *** [0.000] −33.381 *** [0.000] 589.096 *** [0.000] 379.076 *** [0.000]
Individual intercept and trend −33.893 *** [0.000] −31.705 *** [0.000] 598.819 *** [0.000] 4538.01 *** [0.000]
None −35.068 *** [0.000] 858.194 *** [0.000] 4366.23 *** [0.000]
TSC
(level)
Individual intercept −5.214 *** [0.000] −4.060 *** [0.000] 95.287 *** [0.000] 132.095 *** [0.000]
Individual intercept and trend −0.446 [0.327] -0.538 [0.295] 59.588 ** [0.023] 173.970 *** [0.000]
None 3.969 *** [0.000] 109.026 **** [0.000] 115.136 *** [0.000]
D(TSC)
(first
difference)
Individual intercept −18.533 *** [0.000] −19.119 *** [0.000] 330.858 *** [0.000] 333.604 *** [0.000]
Individual intercept and trend −15.846 *** [0.000] −19.541 *** [0.000] 390.267 *** [0.000] 904.160 *** [0.000]
None −23.366 *** [0.000] 507.458 *** [0.000] 759.408 *** [0.000]
VRCA
Individual intercept −2.623 *** [0.004] −2.536 *** [0.005] 66.398 *** [0.005] 83.500 *** [0.000]
Individual intercept and trend −5.116 *** [0.003] −5.928 *** [0.000] 125.040 *** [0.000] 360.909 *** [0.000]
None 1.198 [0.115] 51.183 [0.110] 61.339 ** [0.016]
D(VRCA)
Individual intercept −25.151 *** [0.000] −25.665 *** [0.000] 462.757 *** [0.000] 489.980 *** [0.000]
Individual intercept and trend −25.945 *** [0.000] −29.320 *** [0.0000] 749.123 *** [0.0000] 2409.670 *** [0.000]
None −30.301 *** [0.000] 747.591 *** [0.000] 1137.38 *** [0.000]
Notes: denotes the P-value. *, **, and *** denote the significant level of 10%, 5%, and 1%, respectively. Source:
Authors’ own research, 2019.
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As our results show, the variables are stationary time series of level data. Under these conditions,
the traditional cointegration tests are not necessary, and we can skip the second step of the analysis.
The long-range relations between the investigated time series have been analysed by causality
and regression analysis. The Dumitrescu–Hurlin test of panel data on causality indicates a strong,
bidirectional relationship between the number of patents and publications in Table 4. The number
of patents significantly influences the Balassa index and the Volrath index, but not the value of
Trade Specialisation Coefficient (TSC). A possible explanation of this result is that rich countries have
increased imports of medical products. Interestingly, there is a significant relationship between the
trade specialization and the Volrath competitiveness index. The rising competitiveness index increases
the R&D expenditures and the intellectual output. This can be explained by the fact that the increasing
role of a given sector in the economy generates further propensity to invest into the research and
development in the sector concerned.
Table 4. Results of the Dumitrescu–Hurlin panel causality test.
Hypothesis W-Statistics Z-bar Statistics Probability
PAT→PUB 15.16 2.29 0.02
PAT→RCA 20.24 4.46 0.00
PAT→RD 10.86 0.45 0.65
PAT→TSC 11.56 0.75 0.45
PAT→VRCA 13.90 1.75 0.08
PUB→PAT 12.67 1.22 0.22
PUB→RCA 12.67 1.23 0.22
PUB→RD 8.90 −0.38 0.70
PUB→TSC 16.66 2.93 0.00
PUB→VRCA 16.29 2.77 0.01
RCA→PAT 20.83 4.71 0.00
RCA→PUB 15.53 2.44 0.01
RCA→RD 17.34 3.22 0.00
RCA→TSC 20.77 4.68 0.00
RCA→VRCA 11.19 0.60 0.55
RD→PAT 15.93 2.62 0.01
RD→PUB 20.85 4.72 0.00
RD→RCA 17.43 3.26 0.00
RD→TSC 14.54 2.02 0.04
RD→VRCA 12.92 1.33 0.18
TSC→PAT 13.20 1.45 0.15
TSC→PUB 9.95 0.07 0.95
TSC→RCA 16.71 2.95 0.00
TSC→RD 12.19 1.02 0.31
TSC→VRCA 11.38 0.67 0.50
VRCA→PAT 13.79 1.70 0.09
VRCA→PUB 10.46 0.28 0.78
VRCA→RCA 11.36 0.67 0.51
VRCA→RD 14.18 1.87 0.06
VRCA→TSC 20.18 4.43 0.00
Source: Authors’ own research, 2019.
The Arellano–Bond method applied to determine the long-run relationships did not result in
significantly different lag values; therefore, we have focused only on the coefficients of different
independent variables in Table 5. The effect of the number of patents on TSC is rather obvious. In the
case of publications and R&D resources, this relation is less evident.
Results of the calculations support hypotheses H1 and H2. Indeed, there is a strong relationship
between resources and intellectual output. Hypotheses H3 and H4 have been supported, but it should
be highlighted that competitiveness is a multidimensional concept, thus the correlation between
different determinants of competitiveness varies. Hypothesis H7 has been proven in the case of TSC
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and Vollrath indices of competitiveness. Hypothesis H6 has been supported, but H5 could not be
proven as the number of publications does not increase the patents.
Table 5. Results of the Arellano–Bond test.
Independent Variables
Dependent Variables
Balassa Index of
Competitiveness
Trade Specialisation
Coefficient
Vollrath Index of
Competitiveness
Variables in the Level
Resources for research
and development 0.236 −1.38 1.29
Number of publications 0.385 1.96 * 2.72 **
Number of patents 0.141 2.08 ** 0.94
Constant 0.90 −3.66 −6.59
* and ** denote the significant level of 10% and 5%. Source: Authors’ own research, 2019.
The results of the Hasuman test show that the random effects model is more appropriate in the
case of level data (Table 6).
Table 6. Results of the Hasuman test.
Coefficients of
Fixed Effect Model
Coefficients of
Random Effect Model Difference Standard Error
Dependent variable: RCA, level
Chi square: 9.05**
RD 0.25 0.22 0.03 0.03
PUB −0.10 −0.24 0.14 0.05
PAT 0.11 0.14 −0.03 0.01
Dependent variable: TSC, level
Chi square: 9.44**
RD −0.03 −0.01 −0.02 0.01
PUB 0.06 0.03 0.03 0.01
PAT 0.01 0.02 0.00 0.00
Dependent variable: VRCA, level
Chi square: 19.94*
RD 0.02 0.01 0.00 0.00
PUB 0.12 0.09 0.02 0.01
PAT 0.01 0.02 -0.01 0.00
Source: Authors’ own research, 2019.
Results of the FE–OLS have not yielded a significant, positive relationship between the number
of patents, the number of academic publications and the RCA index (Table 7). In the case of the TSC
index, the number of patents has been significant to the value of the TSC index. The value of the
Volrath index has been positively influenced by the number of patents and publications. This fact
highlights the importance of intellectual output necessary to achieve long-range competitiveness, as
shown in Table 7.
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Table 7. Results of FE–OLS analysis.
Balassa Index of Revealed Competitive Advantages
Coefficient Std.error Z P > |z|
LGRD 0.222 0.078 2.860 0.004
LGPUBL 0.236 0.111 2.120 0.034
LGPAT 0.139 0.045 3.090 0.002
CONST −0.114 0.264 −0.430 0.665
Trade Specialization Coefficient
Coefficient Std.error Z P > |z|
LGRD −0.009 0.027 −0.340 0.734
LGPUBL 0.031 0.039 0.790 0.431
LGPAT 0.048 0.015 3.200 0.000
CONST −0.451 0.098 −4.620 0.000
Vollrath Index of Competitive Advantages
Coefficient Std.error Z P > |z|
LGRD 0.014 0.023 0.630 −0.030
LGPUBL 0.094 0.032 2.880 0.030
LGPAT 0.018 0.013 1.420 −0.007
−1.062 0.093 −11.460 −1.244
Source: Authors’ own research, 2019.
Contrary to our previous expectations, there were no significant causal relationships between the
financial resources allocated to R&D by business enterprises and the Balassa competitiveness index.
In this way, hypothesis H7 is not supported. On the contrary, the material resources allocated to RD
are considerably influenced by the Balassa index in numerous countries in Table 8. This—at first
surprising—fact can be explained by the high level of complexity of pharmaceutical development (the
time window is relatively short to offer a possibility to apply longer—e.g., >7 years – lags), but the
changes in the relative importance of the pharmaceutical sector involve a change in the amount of
money allocated for research and development.
Table 8. Results of Granger causality analysis on the effect of the monetary resources allocated for R&D
on the Balassa index of revealed comparative advantages and the trade specialisation coefficient.
Dependent Variable Monetary Resources, Allocated for R&D
Independent Variable Balassa Index of Competitiveness Trade Specialisation Coefficient
Chi-Square Degrees ofFreedom (df) Prob. Chi-Square df Prob.
Greece 4.8385 2 0.089 * 5.8715 2 0.091 *
Hungary 11.251 5 0.046 ** 13.4157 5 0.008 **
Mexico 16.527 2 0.000 *** 17.0123 2 0.000 ***
Sweden 7.5469 2 0.023 ** 8.1547 2 0.009 ***
Switzerland 13.618 4 0.008 *** 14.872 4 0.000 ***
* significant at 10% level, ** significant at 5% level, *** significant at 1% level. Source: Authors’ own research, 2019.
There has been a significant causal relationship between the number of pharmaceutical patents
and the Balassa index of revealed competitiveness, supporting hypothesis H4 in Table 9. It is important
to emphasise the relatively long lag periods (at least 4 years). Obviously, the TSC values show more
significant differences than the RCA. This fact shows the importance of the time-factor, as well as
the indirect effect between R&D resources and competitiveness. Our results have not provided a
conclusive result regarding the effect of the number of patents on competitiveness.
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Table 9. Results of Granger causality analysis on the effect of the number of patent applications on the
Balassa index of revealed competitiveness.
Countries
Dependent Variable: Balassa Index of
Competitiveness Trade Specialisation Coefficient
Independent Variable: Number of Patents Independent Variable: Number of Patents
Chi-Square Chi-Square df Chi-Square Chi-Square df
Austria 19.461 8 0.012 ** 22.214 8 0.000
Australia 16.159 8 0.056 * 17.221 8 0.022 **
Denmark 14.235 6 0.027 ** 14.005 6 0.020
Finland 16.052 8 0.041 ** 16.987 8 0.038 **
France 8.0202 8 0.431 9.222 8 0.412
Germany 12.726 6 0.047 ** 12.213 6 0.057 *
Greece 36.338 8 0.000 *** 39.477 8 0.000 ***
Ireland 36.263 8 0.000 *** 38.997 8 0.000 ***
Italy 13.787 8 0.087 * 14.12 8 0.075 *
Netherlands 12.805 6 0.046 ** 11.128 6 0.053 *
Norway 19.559 6 0.003 *** 21.125 6 0.001 ***
Spain 21.520 8 0.005 *** 22.547 8 0.002 **
Switzerland 15.667 6 0.015 ** 18.142 6 0.000 ***
United Kingdom 21.056 8 0.007 *** 20.145 8 0.009 **
United States 17.171 8 0.028 ** 16.125 8 0.0312 **
Source: Authors’ own research, 2019. *significant at 10% level, ** significant at 5% level, *** significant at 1% level.
6. Conclusions
Based on the analysis performed, it is evident that the different indicators investigated always
contain a relatively considerable lag. This highlights the crucial importance of strategic thinking
in decision making concerning pharmaceutical-related research and development. It is clear that
there is a direct, important relationship between the material resources allocated to R&D, and the
number of patents, as well as competitiveness. This fact proves that without a long-range strategy
and considerable material resources allocated to R&D, there is no possibility to improve a competitive
position in the international pharmaceutical market. It is an extremely important lesson to learn, i.e.,
that the innovation system in general and in the pharmaceutical sector, in particular, has a considerable
lag: it is an over-simplification to expect rapid results from an increase in financial resources, and
vice versa: the current limitations on resources devoted to R&D will limit practical healing work after
several decades and substantial institutional reforms are expected to be required in the future [91].
It is important to see that our data contained only the financial resources allocated by business
entities for R&D. It can be concluded that, in some cases, central (governmental) resources are necessary
to bolster competitiveness. Based on the results, the three recommendations for the future development
of research policies are as follows:
1. The boosting effect of the state is a necessary development of R&D activity even in branches
dominated by large-scale enterprises.
2. The optimal resource utilization for R&D requires international cooperation because the time
between the achievement of academic results and economic advances is rather long and the
risk is relatively high—there is no straightforward relationship between intellectual success and
international competitiveness.
3. The efficiency of resources allocated to R&D activity can be evaluated and measured by economic
indicators only in a long-range perspective.
4. Currently, increasingly complex regulation related to the introduction of new pharmaceutical
products increases the time-gap between the conceptualisation of new innovation and its
introduction to the market.
In the future, an important direction of research will be the application of panel-cointegration
methods for obtaining a more accurate picture of the relationship between different factors influencing
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the competitiveness of the pharmaceutical industry. It should be taken into consideration that, with
passing time, the longer time series will offer a more favourable possibility to analyse the interplay of
different causes. Last but not least, it should be mentioned that an enterprise-level investigation could
shed light on important differences between the effect of innovation in the case of generic and brand
pharmaceutical companies.
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